BMJ Open

Use of combination therapy in the treatment of primary osteoporosis: protocol for a network meta-analysis of randomised trials

Shenghan Lou, Houchen Lv, Yuxiang Chen, Licheng Zhang, Peifu Tang

ABSTRACT

Introduction: The existing medications approved for treatment of primary osteoporosis can be divided into antiresorptive drugs and anabolic drugs. According to the mechanisms of action, the combined therapy may produce a synergistic effect on bone mineral density (BMD) compared with monotherapy, and thus improves the efficacy of fracture resistance. This network meta-analysis aims to compare the efficacies of different combined methods for the treatment of primary osteoporosis.

Methods and analysis: MEDLINE, EMBASE and Cochrane databases will be searched to identify all randomised controlled trials (RCTs) and quasi-RCTs that evaluate the effectiveness of combined therapy versus monotherapy for primary osteoporosis. The primary outcome will be the BMD changes at the lumbar spine and total hip, and the secondary outcome will be the risks of vertebral fracture and non-vertebral fracture. The efficacies of different combined methods will be compared via traditional pairwise meta-analysis, trial sequential analysis and Bayesian network meta-analysis. Risk of bias will be assessed using the Cochrane tool and the quality of evidence will be assessed using the Grading of Recommendations Assessment, Development and Evaluation for network meta-analysis.

Ethics and dissemination: Ethical approval is not required because this is a protocol for a systematic review without including confidential personal data or data on interventions on patients. Our results will be published in a peer-review journal.

Trial registration number: PROSPERO CRD42016038569.

INTRODUCTION

Rationale

Osteoporosis is characterised by low bone mass and microarchitectural bone tissue deterioration.1 Owing to the high mortality and morbidity, osteoporosis-related fractures become a formidable public health threat.2,3 The annual cost of osteoporosis-related fractures in the USA was estimated to be $16.9 billion in 2005 and predicted to rise to around $25.3 billion by 2025.4

Currently, the medications approved for osteoporosis treatment can be mainly divided into two categories: (1) antiresorptive drugs including bisphosphonates,5 hormone replacement therapy,6 denosumab,7 raloxifene8 and calcitonin,9 and (2) anabolic drugs such as parathyroid hormone (PTH),10 peptide PTH (1–34) (teriparatide)11 and the full-length molecule PTH (1–84).12 Despite the wide expansion of therapeutic options for osteoporosis over the past two decades, there is still no approved therapy that can fully restore skeletal integrity in most osteoporosis patients. Thus, the options for severe osteoporosis patients remain limited.13

Based on the mechanisms of action, there is growing interest in combined therapy of antiresorptive and anabolic drugs in recent years to improve the treatment efficacy. The underlying hypothesis is that combined therapy versus monotherapy may cause an

Strengths and limitations of this study

- This is the first systematic review with network meta-analysis aiming to examine which combined therapy intervention is the best for improving bone mineral density in patients of primary osteoporosis.
- Our results will help clinicians to make informed decision about combined therapy of primary osteoporosis, and guide researchers to conduct and report future research on this topic.
- The strengths of this review are the wide search strategy, use of trial sequential analysis to evaluate the power and the necessary sample size, and use of Grading of Recommendations Assessment, Development and Evaluation to evaluate the certainty of evidences.
- A possible limitation is that the results may yield significant heterogeneity that cannot be explained.
additive effect on bone formation and bone resorption inhibition, and produce a synergistic effect on bone mineral density (BMD), improving the efficacy of fracture resistance. The combination of various anabolic and antiresorptive drugs compared with monotherapy attempts to obtain superior bone mass and strength effects. However, some studies support the hypothesis whereas other studies fail to observe significant differences between combined therapy and monotherapy. To date, the findings are still controversial among studies and the effects of combined therapy are still quite unclear.

Recently, there were three systematic reviews and meta-analyses on combined therapy for the management of primary osteoporosis. However, all three studies suffer from one or more of the following limitations: (1) The included articles are not comprehensive; (2) Eligible trials do not meet the inclusion criteria; and (3) There is no established hierarchy to determine which combined therapy might be the best for the treatment of primary osteoporosis. To the best of our knowledge, there is no network meta-analysis examining the effects of combined therapy on primary osteoporosis.

The purpose of our study is to carry out a network meta-analysis comparing the efficacy of different combined methods for the treatment of primary osteoporosis based on existing randomised controlled trials (RCTs) and ranking these methods for practical consideration. This duration of study was expected to be from May to December 2016.

**Objective**

The objective of this network meta-analysis of RCTs is to determine if the combined therapy of antiresorptive and anabolic drugs outperforms monotherapy in primary osteoporosis, and determine which combined therapy is best to improve BMD in these patients.

**METHODS**

**Design**

This systematic review and NMA protocol was registered in the PROSPERO International Prospective Register of Systematic Reviews (CRD42016038569). This protocol will be developed following the guidelines from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P).

**Eligibility criteria**

**Participants**

Women or men aged ≥45 years old with a high risk of fracture can be included. Both treatment-naive and treatment-experienced patients will be included. High fracture risk is defined as follows: T score ≤−2.5 at the spine, hip or femoral neck; T score ≤−2.0 with at least one BMD-independent risk factor; or T score ≤−1.0 with history of fragility fracture. Participants with secondary osteoporosis will be excluded.

**Interventions**

Any combined therapy of anabolic and antiresorptive drugs will be included. The combined therapy is defined as concomitant use of anabolic and antiresorptive drugs. Calcium and vitamin D supplements are considered as adjuncts to drug therapy, rather than antiresorptive drugs.

**Comparators**

Monotherapy of either antiresorptive or anabolic drugs alone, and antiresorptive or anabolic drugs plus placebo, are defined as the comparator.

**Outcomes**

The primary outcome will be BMD variation at the lumbar spine and total hip. The secondary outcome will be the risk of vertebral fracture and non-vertebral fracture. The risk of fracture is measured by the occurrence of fractures or by Fracture Risk Assessment Tool (FRAX). BMD is measured by dual energy X-ray absorptiometry (DXA).

**Study design**

All relevant RCTs and quasi-RCTs will be included. Quasi-RCTs are trials that use the quasi-random method (eg, allocation by date of birth, day of the week, medical record number or month of the year) of allocating participants to different interventions.

**Time**

Studies of any duration conducted at any time will be included.

**Other**

Unpublished and published studies written in any language will be included.

**Data sources and search**

We will systematically search MEDLINE, EMBASE and Cochrane Library from inception to 10 May 2016, with no language restrictions. We also will search ClinicalTrials.gov (http://www.clinicaltrials.gov) and screen the references of both retrieved articles and relative reviews to further identify potentially eligible trials. The searches will be conducted by two authors independently (SL and YC).

Search strategies will be developed using text words as well as Medical Subject Headings (MeSH) associated with terms relevant to osteoporosis, fracture, teriparatide, PTH, together with RCT. As there are diverse antiresorptive drugs, in order to achieve more comprehensive search results, we will ignore the search terms relevant to antiresorptive drugs. The full search strategies used in MEDLINE, EMBASE and Cochrane Library are provided in online supplementary file S1.
Study selection

The search results will be imported into EndNote X7. Two authors (SL and HL) will independently review all titles and abstracts identified from the literature searches and exclude the studies that obviously do not fulfill the inclusion criteria. Then the full texts of the remaining studies will be reviewed to determine whether they meet the inclusion criteria. Any disagreement will be resolved through discussion or be arbitrated by a third reviewer (YC). The process of study selection from databases will be shown in a PRISMA-compliant flow chart (figure 1).

Data extraction

Information will be extracted from all eligible publications carefully and independently by two authors (SL, HL or YC). The data extracted by a single author (SL) will be double-checked by a second author (HL or YC), and discrepancies will be resolved through discussion. The following data will be extracted from each study: first author, year of publication, number of patients, study design, interventions and outcomes. The extracted data will be entered into a standardised Excel file (Microsoft Corporation).

As for missing data in the included trials, we will seek online supplementary appendices or contact the corresponding authors to obtain the missing data and extract the data only presented in figures using digital calipers. We will email the corresponding authors, explaining the study’s objective and asking for the original data. We will also inform all the corresponding authors that our paper would appropriately cite and acknowledge their articles. If there is no reply, we will send reminder emails at 2, 4 and 8 weeks after the initial email. If there is still no reply after 12 weeks, we will just perform a descriptive review and summarise the evidences. To minimise inconvenience caused these authors, we will only ask for the data that are necessary for this analysis.

If the original data are not available, we will try to calculate the data through the available coefficients. For example, we will impute the mean from median and SD for SE, IQR, or p value according to the Cochrane Handbook for Systematic Reviews of Interventions.

Outcomes and prioritisation

The primary goal of osteoporosis treatment is to prevent bone fractures. Vertebral fractures are considered as the most prevalent osteoporosis-associated fractures. Hip fractures are most likely to be the international barometer, because of the significant morbidity and mortality. BMD is a key risk factor of fractures, and treatment-induced BMD changes are robustly related with fracture risk reduction. BMD variation is an important parameter that evaluates the curative effect of antiosteoporotic drugs.

Since vertebral fracture is the most prevalent complication of osteoporosis and hip fracture is the most devastating complication, the primary outcome will be the BMD changes at the lumbar spine and total hip and the secondary outcome will be the risk of vertebral fracture and non-vertebral fracture.

Current guidelines recommend that the long-term use of either antiresorptive drugs or anabolic drugs should be limited to 18–24 months. Thus, to more clearly explore the effect of combined therapy, we will divide the results into short-term period (6–12 months) and long-term period (18–24 months).

Risk-of-bias assessment

Two authors (SL and HL) will independently assess the risk of bias. Any disagreement will be resolved through discussion or will be judged by a third reviewer (YC). Risk of bias will be assessed by the Cochrane tool described in the Cochrane Handbook. The following categories are specified: (1) random-sequence generation (selection

---

**Figure 1.** The primary selection process. RCT, randomised controlled trial.
bias); (2) allocation concealment (selection bias); (3) blinding of participants and personnel (performance bias); (4) blinding of outcome assessment (detection bias); (5) incomplete outcome data (attrition bias); (6) selective reporting (reporting bias); (7) other bias. Each category is divided into three levels: low risk, unclear risk and high risk.

Statistical analysis
Treatments will be directly compared via traditional pairwise meta-analysis on a random effects model, which provides more conservative estimated effects. To assess the heterogeneity of results from individual studies, we will use Cochrane’s Q statistic, the I² statistic (I²>50% as a threshold indicating significant heterogeneity) and p values (p<0.10 as a threshold indicating significant heterogeneity). The traditional pairwise meta-analysis will be performed on Review Manager 5.3. Continuous outcomes will be expressed as standardised mean difference (SMD) and 95% CI, while dichotomous outcomes will be expressed as risk ratio (RR) and 95% CI.

Bayesian network meta-analysis will be performed on Markov chain Monte Carlo method in WinBUGS V1.4.3, and other analyses will be carried out and presented on STATA V.13.0. The fixed and random effects models with vague priors for multiarm trials will be used. The model fit will be measured using the deviance information criterion (DIC), and the model with the lowest DIC will be preferred (difference ≥3 indicates significant). Dichotomous outcomes will be presented as RR with 95% credibility interval (CrI), while continuous outcomes will be computed by SMD with 95% CrI. The model convergence will be assessed by trace plots and Brooks-Gelman-Rubin plots. After that, the final output will be produced using 50 000 burn-in and 100 000 simulations. Then the node-splitting method will be used to detect the consistency between direct and indirect evidences. The probability of each treatment being the most effective will be calculated and graphically ranked with rankograms. The probability will be summarised and reported as the surface under the cumulative ranking area (SUCRA). SUCRAs will be expressed as percentages: 100% for the best treatment and 0% for the worst treatment. If the data are not suitable for synthesis, we will perform a descriptive review and summarise the evidences.

Trial sequential analysis (TSA)
In a meta-analysis, the risk of type I error may be increased due to the random errors because of sparse data and repetitive testing of accumulating data. TSA is a method for meta-analysis in order to correct such risk. It provides the necessary sample size for a meta-analysis and determines whether the evidences are reliable and conclusive. In our TSA, we will use one-sided tests, with type I error at 5% and power at 80%. The required information size will be calculated based on a relative risk reduction of 20% in main outcomes. These analyses will be performed on TSA 0.9 β.

Meta-biases
If heterogeneity is detected, the following subgroup analyses will be performed: sex (male or female); duration of treatment (same or different durations); history of treatment (treatment-naïve or treatment-experienced); dose of anabolic drugs (common dose or others); sample size (<50 or ≥50); risk of bias (low risk or high risk).

If enough trials per comparison are included, a sensitivity analysis will be conducted to examine the robustness of our analysis. Furthermore, small-study effects will be assessed using comparison-adjusted funnel plots.

Quality of evidence
Two authors (SL and HL) will independently evaluate the quality of evidence for the primary and secondary outcomes according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) four-step approach for rating the quality of treatment effect estimates from network meta-analysis. (1) present direct and indirect treatment estimates for each comparison of the evidence network; (2) rate the quality of each direct and indirect effect estimate; (3) present the network meta-analysis estimate for each comparison of the evidence network; and (4) rate the quality of each network meta-analysis effect estimate. The quality of evidence will be classified by the GRADE group into four levels: high quality, moderate quality, low quality and very low quality. This process will be performed using GRADE pro V3.6 software (http://www.gradeworkinggroup.org/).

ETHICS AND DISSEMINATION
Ethical approval is not required given that this is a protocol for a systematic review including no confidential personal data and no data on interventions on patients. The procedures of network meta-analysis will be conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) extension statement for network meta-analyses of healthcare interventions, and the results will be submitted to at a professional conference and published in a peer-reviewed journal.

Contributors PT is the guarantor. PT, LZ and SL contributed to the conception and design of this study protocol. SL registered the protocol with the PROSPERO database and edited the draft protocol. The search strategy was developed by SL and YC. SL and HL will screen titles, abstracts and full-text copies of the studies after the literature search. SL, HL or YC will extract information of the included studies after screening. LZ will check the data entry for accuracy and completeness. PT and LZ will give advice for data analysis and presentation of study result. All the authors drafted and critically reviewed this manuscript and approved the final version.

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785–95.
2. Johnell O, Kanis JA. An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int 2004;15:971–8.
3. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726–33.
4. Lang R, Jeppson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 2007;22:465–75.
5. Thorsteinsson AL, Vestergaard P, Eiken P. External auditory canal and middle ear cholesterol otorrhea and osteonecrosis in bisphosphonate-treated osteoporosis patients: a Danish national register-based cohort study and literature review. Osteoporos Int 2014;25:1937–44.
6. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized controlled trials. JAMA 2006;299:1–9.
7. Cummings SR, San Martin J, McClung MR, et al. Incidence and risk of osteoporosis-related fractures in women 50 years and older in the United States, 2005–2025. J Bone Miner Res 2007;22:2529–37.
8. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756–65.
9. Cranney A, Tugwell P, Zytaruk N, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:524–8.
10. Cranney A, Tugwell P, Zytaruk N, et al. Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:540–51.
11. Shen L, Xie X, Su Y, et al. Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials. PLoS ONE 2011;6:e26267.
12. Neer RM, Arnaud CD, Zanchetta JR, et al. Parathyroid hormone (1–84) in combination treatment: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab 2009;94:377–80.
13. Fogelman I, Fordham JN, Fraser WD, et al. Parathyroid hormone (1–84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy. Calcif Tissue Int 2008;83:85–92.
14. Cosman F, Winters RA, Recknor C, et al. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab 2009;94:1905–11.
15. Finkelstein JS, Leder BZ, Burnett SM, et al. Effects of teriparatide, alendronate, or both on bone turnover in men. J Clin Endocrinol Metab 2006;91:2882–7.
16. Ste-Marie LG, Schwartz SL, Hossain A, et al. Effects of teriparatide and denosumab, or treatment with zoledronic acid plus subcutaneous teriparatide [rPTh(1–34)] on bone mineral density. Ann Intern Med 2011;155:593–602.
17. Cosman F, Winters RA, Recknor C, et al. Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate. Osteoporos Int 2008;19:1055–65.
18. Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2005;349:1216–26.
19. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med 2005;353:555–65.
20. Deal C, Omozi M, Schwartz EN, et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 2005;20:1905–11.
21. Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003;349:1216–26.
22. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1027–1035.
23. Reeve J, Mitchell A, Tellez M, et al. Treatment with parathyroid peptides and estrogen replacement for severe postmenopausal vertebral osteoporosis: prediction of long-term responses in spine and femur. J Bone Miner Metab 2001;19:102–14.
24. Cosman F, Nieves J, Parham L, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001;16:925–31.
25. Lane NE, Sanchez S, Modin GW, et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998;102:1627–33.
26. Cosman F, Nieves J, Woelfert L, et al. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 1998;13:1051–8.
27. Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997;350:550–5.
28. Li X, Chen W, Lin Y. The efficacy of parathyroid hormone analogues in combination with bisphosphonates for the treatment of osteoporosis: a meta-analysis of randomized controlled trials. Medicine 2015;94:e1156.
29. Song J, Jin Z, Zhang H, et al. Single and combined use of human parathyroid hormone (PTh) (1–34) on areal bone mineral density (aBMD) in postmenopausal women with osteoporosis: evidence based on 9 RCTs. Med Sci Mont 2014;20:2624–2.
30. Zhang G, Qian J, Zhu Y. Parathyroid hormone plus alendronate in osteoporosis: a meta-analysis of randomized controlled trials. Int J Clin Exp Med 2015;8:3338–46.
31. Shamsaeer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647.
42. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.

43. Morin SN, Lix LM, Majumdar SR, et al. Temporal trends in the incidence of osteoporotic fractures. Curr Osteoporos Rep 2013;11:263–9.

44. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761–7.

45. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005;20:1186–94.

46. Austin M, Yang YC, Vittinghoff E, et al. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res 2012;27:887–93.

47. Chen P, Miller PD, Delmas PD, et al. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 2006;21:1785–90.

48. Seibel MJ, Naganathan V, Barton I, et al. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J Bone Miner Res 2004;19:323–9.

49. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437–43.

50. Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002;87:1586–92.

51. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002;112:281–9.

52. Whitaker M, Guo J, Kehoe T, et al. Bisphosphonates for osteoporosis—where do we go from here? N Engl J Med 2012;366:2048–51.

53. Black DM, Bauer DC, Schwartz AV, et al. Continuing bisphosphonate treatment for osteoporosis—for whom and for how long? N Engl J Med 2012;366:2051–3.

54. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.

55. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.

56. Spiegelhalter DJ, Best NG, Carlin BP, et al. Bayesian measures of model complexity and fit. J R Stat Soc: Series B 2002;64:583–639.

57. Gelman A, Rubin DB. Inference from iterative simulation using multiple sequences. Stat Sci 1992;7:457–72.

58. Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat Assoc 2006;101:447–59.

59. Dias S, Welton NJ, Caldwell DM, et al. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010;29:932–44.

60. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64:163–71.

61. Brok J, Thorlund K, Wetterslev J, et al. Apparently conclusive meta-analyses may be inconclusive—trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. Int J Epidemiol 2009;38:287–98.

62. Wetterslev J, Thorlund K, Brok J, et al. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 2008;61:64–75.

63. Chaimani A, Higgins JP, Mavridis D, et al. Graphical tools for network meta-analysis in STATA. PLoS ONE 2013;8:e76654.

64. Puhu MA, Schünemann HJ, Murad MH, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014;349:g5630.

65. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777–84.